MOKAN Wealth Management Inc. Sells 12,060 Shares of Gilead Sciences, Inc. $GILD

MOKAN Wealth Management Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 62.3% in the third quarter, Holdings Channel.com reports. The fund owned 7,292 shares of the biopharmaceutical company’s stock after selling 12,060 shares during the period. MOKAN Wealth Management Inc.’s holdings in Gilead Sciences were worth $809,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Brighton Jones LLC boosted its stake in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new stake in Gilead Sciences in the fourth quarter worth about $215,000. Sivia Capital Partners LLC boosted its position in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares in the last quarter. CHICAGO TRUST Co NA grew its holdings in shares of Gilead Sciences by 25.9% during the 2nd quarter. CHICAGO TRUST Co NA now owns 2,900 shares of the biopharmaceutical company’s stock worth $322,000 after acquiring an additional 597 shares during the period. Finally, Fifth Third Bancorp grew its holdings in shares of Gilead Sciences by 2.7% during the 2nd quarter. Fifth Third Bancorp now owns 378,923 shares of the biopharmaceutical company’s stock worth $42,011,000 after acquiring an additional 9,822 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $70,740,911.34. The trade was a 1.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the sale, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This represents a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 141,757 shares of company stock valued at $17,569,112 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $131.14 on Friday. The business has a fifty day moving average price of $123.76 and a 200-day moving average price of $118.46. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company has a market capitalization of $162.70 billion, a PE ratio of 20.33, a PEG ratio of 0.68 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $92.21 and a 1-year high of $133.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Analyst Ratings Changes

A number of research firms have recently commented on GILD. Rothschild & Co Redburn raised their target price on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research note on Tuesday. Royal Bank Of Canada raised their price objective on Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a research report on Tuesday. Needham & Company LLC boosted their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Daiwa Capital Markets increased their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Finally, The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $133.52.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.